Cresp 60mcg (Darbepoetin alfa)

Cresp is an anti-anemic medication containing darbepoetin alfa as its active ingredient. It belongs to the class of recombinant erythropoietins and is used for the management of anemia associated with anticancer chemotherapy.

MECHANISM OF ACTION

Darbepoetin alfa is a hyperglycosylated analog of human erythropoietin with an extended half-life. It binds to erythropoietin receptors on erythroid progenitor cells in the bone marrow, activating the JAK2/STAT5 signaling cascade. This stimulates the proliferation, differentiation, and maturation of red blood cells, thereby increasing hemoglobin levels.

INDICATIONS

• Treatment of anemia in adult patients with non-Hodgkin’s lymphoma, multiple myeloma, and other solid tumors undergoing chemotherapy.
• Prevention of red blood cell transfusions in patients with anticipated chemotherapy-induced anemia.

IMPORTANT SAFETY INFORMATION (RISKS)

Use of Cresp is associated with an increased risk of thromboembolic events (deep vein thrombosis, pulmonary embolism, stroke), hypertension, and reduced survival when targeting hemoglobin levels above 12 g/dL.
Contraindications: uncontrolled arterial hypertension and hypersensitivity to darbepoetin alfa or any excipients of the formulation.

DOSING REGIMEN

• Recommended initial dose: 60 mcg once weekly, administered subcutaneously or intravenously.
• Alternative regimen: 500 mcg once every 3 weeks.
• Initiate treatment when hemoglobin is ≤10 g/dL.
• Discontinue therapy if no response is observed after 6–8 weeks.
• Target hemoglobin level: not to exceed 12 g/dL.

CONTRAINDICATIONS

• Hypersensitivity to darbepoetin alfa or any component of the product
• Uncontrolled arterial hypertension
• Patients with a life expectancy of less than 2 months

ADVERSE EFFECTS

Most common adverse reactions include: headache, hypertension, arthralgia, nausea, peripheral edema, thromboembolic events, and injection site reactions.

SPECIAL WARNINGS AND PRECAUTIONS

• Therapy must be administered only under the supervision of an oncologist.
• Assess iron status (ferritin, transferrin saturation) before initiating treatment; administer iron supplementation if deficiency is present.
• Monitor blood pressure and hemoglobin levels 1–2 times per week until stable.

STORAGE CONDITIONS

• Store the injection solution refrigerated at 2°C to 8°C. Do not freeze.
• Once opened, the prefilled syringe may be used for up to 28 days if kept refrigerated.

Disclaimer: Cresp is a potent prescription medication used exclusively under the supervision of an oncologist in a certified medical facility. The information provided on mhp.ooo is for reference purposes only and must not be construed as medical advice or a treatment guide. Self-treatment of oncological conditions is life-threatening.